Literature DB >> 24241822

Does ceruloplasmin differential express in the brain of Ts65Dn: a mouse mode of Down syndrome?

Bin Yu1, Jing Kong, Baoling Xing, Ziqiang Zhu, Bin Zhang, Qiu-Wei Wang, Shi-He Shao.   

Abstract

To investigate the expression of CP in Down syndrome (DS) mouse model, we especially observed the changes in neuronal CP. We systematically analyzed the level of CP in Ts65Dn mouse, including serum CP concentration and enzymatic activity, CP mRNA in brain, the expression of CP protein in brain. The applied technologies were ELISA, chemical colorimetry, RT-PCR, immunohistochemistry. Compared with the control group, there were no differences of significance in the concentration, enzymatic activity and unit activity of serum ceruloplasmin. By RT-PCR, we also found there were no significant differences in the level of CP mRNA. The expression of CP was positive in the endochylema of neuronal cells of both the groups, and there were no significant difference between the two groups. Meanwhile, there were no differences in four regions of the brain (cerebral cortex, hippocampus, thalamus and cerebella). Although the neurotoxic effects of CP related to some neurodegenerative diseases, but whether it does so in DS remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24241822     DOI: 10.1007/s10072-013-1570-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  16 in total

Review 1.  The brain in Down syndrome (TRISOMY 21).

Authors:  Gert Lubec; Ephrem Engidawork
Journal:  J Neurol       Date:  2002-10       Impact factor: 4.849

Review 2.  Dementia and mortality in persons with Down's syndrome.

Authors:  A Coppus; H Evenhuis; G-J Verberne; F Visser; P van Gool; P Eikelenboom; C van Duijin
Journal:  J Intellect Disabil Res       Date:  2006-10

3.  Copper, ceruloplasmin and superoxide dismutase (SOD1) in patients with Down's syndrome.

Authors:  G Tórsdóttir; J Kristinsson; S Hreidarsson; J Snaedal; T Jóhannesson
Journal:  Pharmacol Toxicol       Date:  2001-12

Review 4.  Ceruloplasmin in neurodegenerative diseases.

Authors:  Vadim Vassiliev; Zena Leah Harris; Paolo Zatta
Journal:  Brain Res Brain Res Rev       Date:  2005-11

5.  Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention.

Authors:  Stefano Olivieri; Antonio Conti; Sandro Iannaccone; Carlo V Cannistraci; Alessandro Campanella; Marco Barbariga; Franca Codazzi; Ilaria Pelizzoni; Giuseppe Magnani; Mariasabina Pesca; Diego Franciotta; Stefano F Cappa; Massimo Alessio
Journal:  J Neurosci       Date:  2011-12-14       Impact factor: 6.167

Review 6.  Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome.

Authors:  Andrea Contestabile; Fabio Benfenati; Laura Gasparini
Journal:  Prog Neurobiol       Date:  2010-01-25       Impact factor: 11.685

Review 7.  Down syndrome and Alzheimer disease.

Authors:  B T Hyman
Journal:  Prog Clin Biol Res       Date:  1992

8.  Are the cognitive functions of children with Down syndrome related to their participation?

Authors:  Tanya Rihtman; Esti Tekuzener; Shula Parush; Alex Tenenbaum; Steven J Bachrach; Asher Ornoy
Journal:  Dev Med Child Neurol       Date:  2009-09-16       Impact factor: 5.449

9.  Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease.

Authors:  J R Connor; P Tucker; M Johnson; B Snyder
Journal:  Neurosci Lett       Date:  1993-09-03       Impact factor: 3.046

10.  Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma.

Authors:  Qiulin Liao; Liang Zhao; Xiaodong Chen; Yongjian Deng; Yanqing Ding
Journal:  Clin Exp Metastasis       Date:  2008-03-21       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.